New York State Teachers Retirement System Sells 7,286 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

New York State Teachers Retirement System trimmed its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 356,127 shares of the biopharmaceutical company’s stock after selling 7,286 shares during the period. New York State Teachers Retirement System owned approximately 0.16% of Alexion Pharmaceuticals worth $49,961,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ALXN. Fiduciary Trust Co. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $111,000. Huntington National Bank lifted its holdings in shares of Alexion Pharmaceuticals by 1,084.6% during the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the last quarter. Penserra Capital Management LLC lifted its holdings in shares of Alexion Pharmaceuticals by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $160,000. Finally, Grove Bank & Trust lifted its holdings in shares of Alexion Pharmaceuticals by 194.7% during the second quarter. Grove Bank & Trust now owns 1,347 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 890 shares during the last quarter. Hedge funds and other institutional investors own 94.55% of the company’s stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the prior year, the company posted $1.23 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://sportsperspectives.com/2017/11/02/new-york-state-teachers-retirement-system-sells-7286-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Several equities analysts have recently issued reports on ALXN shares. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a report on Tuesday. Morgan Stanley reiterated an “overweight” rating and set a $153.00 target price (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $163.00 to $175.00 in a report on Tuesday, September 5th. Leerink Swann reiterated an “outperform” rating and set a $182.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, Stifel Nicolaus lowered their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a report on Tuesday, October 24th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $154.01.

In related news, EVP Julie O’neill sold 4,375 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the sale, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock valued at $2,337,251 in the last three months. 4.35% of the stock is currently owned by corporate insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply